Dr Catalina Lopez-Correa has been appointed VP sector development and chief scientific officer of Genome British Columbia after eight years in two senior roles at Genome Quebec. Lopez-Correa announced her departure from Genome Quebec last November just weeks prior to the departure of president and CEO Marc LePage (see page 4) and has taken up her new duties in BC where she will be a key player in implementing the regional centre's 2015-2020 strategic plan. Prior to joining Genome Quebec, she gained extensive experience in the private sector as a principal research scientist with Eli Lilly and Co as part of the pharmacogenomics and translational medicine team where she also helped develop the firm's therapeutics and personalized medicine strategy. Lopez-Correa has also been an evaluator for large multinational projects funded by the European Commission since 2002. She holds an MSc in human genetics from Université Paris Descartes, a PhD in medical biosciences from the Univ of Leuven (Belgium) and a mini MBA from McGill Univ. Stéphanie Lord-Fortaine, senior director of scientific affairs, has replaced Lopez-Correa at Genome Quebec on an interim basis until a selection process for a permanent replacement is completed….